In today’s recent session, 1.5 million shares of the Seres Therapeutics Inc (NASDAQ:MCRB) have been traded, and its beta is 1.91. Most recently the company’s share price was $1.01, and it changed around $0.11 or 12.72% from the last close, which brings the market valuation of the company to $152.95M. MCRB at last check was trading at a discount to its 52-week high of $6.26, offering almost -519.8% off that amount. The share price’s 52-week low was $0.54, which indicates that the recent value has risen by an impressive 46.53% since then. We note from Seres Therapeutics Inc’s average daily trading volume that its 3-month average coming to 5.02 million.
Seres Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.86. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended MCRB as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Seres Therapeutics Inc is expected to report earnings per share of -$0.29 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Instantly MCRB has been showing a green trend so far today with a performance of 12.72% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -27.86% year-to-date, but still up 34.76% over the last five days. On the other hand, Seres Therapeutics Inc (NASDAQ:MCRB) is 58.76% up in the 30-day period.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Seres Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -5.62 percent over the past six months and at a -14.61% annual growth rate that is well below the industry average of 13.10%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -180.60% in revenue this quarter, and will report an increase of 37.80% in the next quarter.
7 analysts expect Seres Therapeutics Inc to make $70k in revenue for the quarter ending Sep 2024. The company’s sales for the same quarters a year ago were $126.47 million and $1.87 million respectively. Forecasts for the next quarter put sales growth at -96.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.22%.
